Insider Trading Alert - CFN, PFE, IACI, GMED And TUP Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 4, 2013, 136 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $597.52 to $378,220,575.33.

Highlighted Stocks Traded by Insiders:

CareFusion (CFN) - FREE Research Report

Leonard Thomas J who is President, Medical Systems at CareFusion sold 1,250 shares at $39.06 on Nov. 4, 2013. Following this transaction, the President, Medical Systems owned 62,299 shares meaning that the stake was reduced by 1.97% with the 1,250 share transaction.

The shares most recently traded at $38.82, down $0.24, or 0.62% since the insider transaction. Historical insider transactions for CareFusion go as follows:

  • 12-Week # shares sold: 42,500
  • 24-Week # shares sold: 63,300

The average volume for CareFusion has been 1.6 million shares per day over the past 30 days. CareFusion has a market cap of $8.3 billion and is part of the health care sector and health services industry. Shares are up 36.11% year to date as of the close of trading on Monday.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. The company has a P/E ratio of 22.4. Currently there are 6 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFN - FREE

TheStreet Quant Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CareFusion Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Pfizer (PFE) - FREE Research Report

Cangialosi Loretta V who is Sr. Vice President, Controller at Pfizer sold 10,000 shares at $31.20 on Nov. 4, 2013. Following this transaction, the Sr. Vice President, Controller owned 174,841 shares meaning that the stake was reduced by 5.41% with the 10,000 share transaction.

The shares most recently traded at $31.25, up $0.05, or 0.16% since the insider transaction. Historical insider transactions for Pfizer go as follows:

  • 12-Week # shares sold: 38,461
  • 24-Week # shares sold: 53,149

The average volume for Pfizer has been 25.3 million shares per day over the past 30 days. Pfizer has a market cap of $206.4 billion and is part of the health care sector and drugs industry. Shares are up 24.29% year to date as of the close of trading on Monday.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The stock currently has a dividend yield of 3.08%. The company has a P/E ratio of 24.5. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PFE - FREE

TheStreet Quant Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

IAC/InterActiveCorp (IACI) - FREE Research Report

Martinez Arthur C who is Director at IAC/InterActiveCorp sold 19,647 shares at $53.03 on Nov. 4, 2013. Following this transaction, the Director owned 14,325 shares meaning that the stake was reduced by 57.83% with the 19,647 share transaction.

The shares most recently traded at $54.83, up $1.80, or 3.28% since the insider transaction.

The average volume for IAC/InterActiveCorp has been 953,800 shares per day over the past 30 days. Shares are up 15.47% year to date as of the close of trading on Monday.

IAC/InterActiveCorp operates as a media and Internet company in the United States and internationally. The stock currently has a dividend yield of 1.76%. The company has a P/E ratio of 19.4. Currently there are 7 analysts that rate IAC/InterActiveCorp a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IACI - FREE

TheStreet Quant Ratings rates IAC/InterActiveCorp as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full IAC/InterActiveCorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Globus Medical (GMED) - FREE Research Report

Davidar David D who is Vice President, Operations at Globus Medical sold 72,722 shares at $18.20 on Nov. 4, 2013. Following this transaction, the Vice President, Operations owned 949,775 shares meaning that the stake was reduced by 7.11% with the 72,722 share transaction.

Demski David M who is President and COO at Globus Medical sold 112,677 shares at $18.59 on Nov. 4, 2013. Following this transaction, the President and COO owned 568,688 shares meaning that the stake was reduced by 16.54% with the 112,677 share transaction.

The shares most recently traded at $18.86, up $0.27, or 1.46% since the insider transaction. Historical insider transactions for Globus Medical go as follows:

  • 12-Week # shares sold: 44,776
  • 24-Week # shares sold: 149,776

The average volume for Globus Medical has been 506,100 shares per day over the past 30 days. Globus Medical has a market cap of $1.8 billion and is part of the health care sector and health services industry. Shares are up 80.93% year to date as of the close of trading on Monday.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of products that promote healing in patients with spine disorders. The company has a P/E ratio of 26.0. Currently there are 6 analysts that rate Globus Medical a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GMED - FREE

TheStreet Quant Ratings rates Globus Medical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Get the full Globus Medical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Tupperware Brands Corporation (TUP) - FREE Research Report

Poteshman Michael S who is Executive Vice President & CFO at Tupperware Brands Corporation sold 2,000 shares at $89.91 on Nov. 4, 2013. Following this transaction, the Executive Vice President & CFO owned 40,576 shares meaning that the stake was reduced by 4.7% with the 2,000 share transaction.

The shares most recently traded at $89.59, down $0.32, or 0.36% since the insider transaction. Historical insider transactions for Tupperware Brands Corporation go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 9,000
  • 24-Week # shares sold: 24,750

The average volume for Tupperware Brands Corporation has been 406,500 shares per day over the past 30 days. Tupperware Brands Corporation has a market cap of $4.7 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 41.87% year to date as of the close of trading on Monday.

Tupperware Brands Corporation operates as a direct seller of various products across a range of brands and categories through an independent sales force worldwide. The stock currently has a dividend yield of 2.73%. The company has a P/E ratio of 24.1. Currently there are 4 analysts that rate Tupperware Brands Corporation a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TUP - FREE

TheStreet Quant Ratings rates Tupperware Brands Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Tupperware Brands Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)